全文获取类型
收费全文 | 201474篇 |
免费 | 17640篇 |
国内免费 | 5702篇 |
专业分类
耳鼻咽喉 | 2188篇 |
儿科学 | 4771篇 |
妇产科学 | 3503篇 |
基础医学 | 19709篇 |
口腔科学 | 4571篇 |
临床医学 | 20570篇 |
内科学 | 35569篇 |
皮肤病学 | 3398篇 |
神经病学 | 13023篇 |
特种医学 | 8195篇 |
外国民族医学 | 23篇 |
外科学 | 25108篇 |
综合类 | 23133篇 |
现状与发展 | 13篇 |
一般理论 | 52篇 |
预防医学 | 17852篇 |
眼科学 | 2958篇 |
药学 | 17958篇 |
119篇 | |
中国医学 | 8956篇 |
肿瘤学 | 13147篇 |
出版年
2024年 | 549篇 |
2023年 | 2042篇 |
2022年 | 4172篇 |
2021年 | 6035篇 |
2020年 | 4820篇 |
2019年 | 3938篇 |
2018年 | 4969篇 |
2017年 | 4842篇 |
2016年 | 4524篇 |
2015年 | 6361篇 |
2014年 | 8085篇 |
2013年 | 10834篇 |
2012年 | 14081篇 |
2011年 | 14521篇 |
2010年 | 11533篇 |
2009年 | 10440篇 |
2008年 | 12233篇 |
2007年 | 12077篇 |
2006年 | 11076篇 |
2005年 | 9695篇 |
2004年 | 8712篇 |
2003年 | 7797篇 |
2002年 | 7285篇 |
2001年 | 5555篇 |
2000年 | 4929篇 |
1999年 | 3671篇 |
1998年 | 1695篇 |
1997年 | 1425篇 |
1996年 | 1345篇 |
1995年 | 1230篇 |
1994年 | 1052篇 |
1993年 | 1017篇 |
1992年 | 2003篇 |
1991年 | 1916篇 |
1990年 | 1655篇 |
1989年 | 1609篇 |
1988年 | 1473篇 |
1987年 | 1306篇 |
1986年 | 1305篇 |
1985年 | 1158篇 |
1984年 | 868篇 |
1983年 | 802篇 |
1982年 | 553篇 |
1981年 | 475篇 |
1979年 | 601篇 |
1978年 | 449篇 |
1975年 | 451篇 |
1974年 | 495篇 |
1973年 | 466篇 |
1972年 | 437篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献42.
43.
44.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献
45.
Femoral access‐related complications during percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL device closure
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
46.
Evaluation of training nurses to perform semi‐automated three‐dimensional left ventricular ejection fraction using a customised workstation‐based training protocol
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
47.
目的:评定LC-MS/MS法测定人血浆中布康唑浓度的不确定度。方法:分析测定过程中不确定度的来源,包括对照品的称量、仪器误差、标准溶液的配制、含药血浆样品的配制、血浆样品的处理、标准曲线的拟合、基质效应、重复性等,评定各来源分量的不确定度,计算合成不确定度和扩展不确定度。结果:人血浆中低(60.0 pg·mL-1)、中(600.0 pg·mL-1)、高(6 400.0 pg·mL-1)浓度布康唑的扩展不确定度分别为5.62,63.90,626.26 pg·mL-1(k=2,P=95%)。结论:LC-MS/MS法测定人血浆中布康唑浓度的不确定度主要由基质效应、血浆样品的处理(提取回收率),仪器误差、重复性(精密度)引入。 相似文献
48.
目的 评价NITI悬臂梁在矫正舌倾下颌磨牙中的临床效果。方法 选择16例单侧下颌第二磨牙舌倾的病例为研究对象,带垫铸造支架连接双侧下颌后牙,提供颌内支抗、解除咬合锁结,0.018英寸×0.025英寸或0.019英寸×0.025英寸NITI悬臂梁提供颊向旋转力矩和压低力。采用Graphpad Prism 6.0 软件对治疗前、后所测数据进行配对 t 检验。结果 所有患牙均获得直立,牙轴变化24°±1.2°(P<0.01),近中舌尖到正中矢状面垂直距离变化(3±0.8) mm(P<0.05),牙周状况良好,咬合关系稳定。结论 铸造支架联合NITI 悬臂梁可提供有效力学机制,矫正舌倾下颌磨牙。 相似文献
49.
50.
F. Murina R. Felice S. Di Francesco L. Nelvastellio I. Cetin 《Gynecological endocrinology》2020,36(5):431-435
AbstractThis study is a single-center, retrospective analysis of postmenopausal women presenting with dyspareunia and vulvar pain, aiming to evaluate relative effectiveness of vestibular CO2 laser therapy as a treatment. Three monthly sessions of laser were performed to each patient and thereafter a three-months follow-up was stablished. A total number of 72 patients undergoing vestibular laser treatment were recruited from patient files in the period between 2016 and 2018. Among these, 39 women also received a concomitant treatment with ospemifene (60?mg/day) during the study period. There was a statistically significant reduction of all the symptoms in both groups up to the three month follow-up. Regarding dryness and dyspareunia, the relief tent to be more prominent in the ospemifene?+?laser group at all follow-ups and remained statistically significant at three-month follow-up. Specifically, vestibular dryness was significantly lower in the ospemifene?+?laser group compared with the laser treatment group (?87% vs???34%, respectively), and the vestibular health score started declining faster in the ospemifene?+?laser group. Although, additional research is needed to understand the mechanism of action, our data shows that a combination regimen of laser and ospemifene may improve clinical effectiveness for long-term treatment of symptoms associated with the under-recognized genitourinary syndrome of menopause. 相似文献